^
CANCER:

Burkitt Lymphoma





Show legend
Group by Gene:
Include preclinical:

0
CD20 inhibitor
rituximab
1
Alkylating agent
cyclophosphamide
2
PI3Kδ inhibitor
idelalisib
3
CD19-targeted CAR-T immunotherapy
PZ01
RIVAC
R-CVAD
4
Chemotherapy
EPOCH-R
R-GDP
RICE
ViPOR
5
T-lymphocyte cell therapy
T-lymphocyte cell therapy
6
CD20 inhibitor, Chemotherapy
CODOX-M + rituximab
7
THF dehydrogenase inhibitor, Dihydrofolic acid reductase inhibitor, Chemotherapy
RIVAC + methotrexate
RICE + methotrexate
8
THF dehydrogenase inhibitor, DNA synthesis inhibitor, Dihydrofolic acid reductase inhibitor, DNA-directed DNAP inhibitor, Chemotherapy
R-CVAD + cytarabine + methotrexate
9
Bifunctional alkylating agent, THF dehydrogenase inhibitor, Topoisomerase II inhibitor, DNA synthesis inhibitor, Dihydrofolic acid reductase inhibitor, DNA-directed DNAP inhibitor
cytarabine + ifosfamide + etoposide IV + methotrexate
10
CD19 inhibitor, CD16A inhibitor, IL-15R stimulant, CD20 inhibitor
rituximab + FT596
11
CD38-targeted antibody-drug conjugate, Ionizing radiation emitter
Actinium-225 conjugated to daratumumab
12
SLC1A5-targeted antibody-drug conjugate, DNA replication inhibitor
MEDI7247
No biomarker
TP53 T175H + PIK3CA H1047R
CD20 positive
LDH elevation
TP53 A159V
CD38 positive
CD19 positive + CD20 positive
LY9 expression
SLC1A5 overexpression